The chief executive officer of MedinCell, Christophe Douat stated thatclinical advancement is set to become a considerable part of the budget of MedinCell and that it will define the time to commercialize their goods. He added that with the addition of Dr. Richard Malamut to the medical board will prove to be very influential to their performance, thanks to his know-how in pharmaceutical advancement, design optimization, as well as clinical trial strategy.
The Medical Advisory Board is made up of esteemed experts from around the globe. Their mission is to council on medical concerns, good development strategies, and extension of portfolio. The Medical Advisory Board meets up at least every quarter of the year to go over the progress of programs and to provide ad hoc guidance. Dr. Richard Malamut will enhance the MAB’s standing thanks to his vast experience in drug development, especially when it comes to pain and the central nervous system.
Dr. Richard Malamut is presently serving as Collegium Pharmaceuticals’ Chief Medical Officer and Executive Vice President. Malamut serve at the Senior Vice President of Global Clinical Development for Pain, Neuropsychiatry, Oncology, and New Therapeutic Entities at Teva Pharmaceuticals, from 2013 to 2016. Previously, he also acted as the Braeburn Pharmaceuticals’ chief medical officer, as well as the CMO of Avanir Pharmaceuticals. He also supported numerous roles with rising responsibilities at Bristol-Myers and AstraZeneca dedicated to early clinical development as well as translational medicine.
Dr. Richard Malamut gained his medical degree from in Philadelphia from Hahnemann University. He completed his residency in Neurology. His fellowship was completed in Neuromuscular ailments. He has also acted, for 17 years, as a board-certified academic and clinical neurologist. He holds over 50 publications in the fields of neuromuscular/autonomic disease, pain medicine, and neurodegenerative disease.